DNTH
Dianthus Therapeutics, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Mar 9 ▲ Dianthus Therapeutics reported full-year 2025 financial results and…
- Mar 12 ▼ Dianthus Therapeutics CEO, R&D head, and CFO-equivalent executed a c…
- May 5 ▲ Dianthus Therapeutics reported Q1 2026 net loss of $40.8M ($0.85/sha…
- Jun 12 ▲ Dianthus Therapeutics posted an updated corporate presentation discl…
- Aug 10 ▼ 3 insiders sell $2.9M at $109.90
- Aug 11 ▼ CEO Marino Garcia and General Counsel Adam Veness executed a cluster…
- Aug 19 ▼ 1 insider sell $326.6K at $117.55
- Sep 1 ▼ 1 insider sell $2.5M at $106.41
- Sep 14 Trial readout: T-90d Trial Readout: Claseprubart (Phase 2)
- Sep 17 ▼ 1 insider sell $2.0M at $101.38
- Oct 27 Roth Capital initiates
- Nov 9 to Nov 12 ▼ 4 days of insider sells: $11.2M by 1 insider, avg $90.52
Signal stack
Where each data set points today.
- InsidersBEARISH
6 insiders sold $19.0M.
- InstitutionsBULLISH
Q3 2026: 34 added (0 new), 14 trimmed or exited.
- AnalystsBULLISH
23 of 24 rate it Buy or better. Every target is above the price.
- Short sellersSTEADY
Short interest +3.2% to 9.28M shares. 10.1 days to cover, ≈16.5% of shares.
- TrendUPTREND
4% above its 50-day average.
- SocialQUIET
No Reddit mentions this week. Last mention Nov 1.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| VANGUARD PORTFOLIO MANAGEMENT LLC | DOUBLED | $136.0M |
| Assenagon Asset Management S.A. | DOUBLED | $64.5M |
| WESTFIELD CAPITAL MANAGEMENT CO LP | ADD | $41.8M |
| Pictet Asset Management Holding SA | ADD | $40.7M |
| VANGUARD FIDUCIARY TRUST CO | ADD | $34.4M |
| Fisher Asset Management, LLC | DOUBLED | $24.0M |
| Artisan Partners Limited Partnership | TRIM | $16.4M |
| Invesco Ltd. | ADD | $14.6M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
24 analystsPrice is below the lowest target. Median implies +46%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Oct 27, 2026 | Roth Capital INITIATE | Buy |
| Oct 15, 2026 | HC Wainwright & Co. REITERATE | Buy |
| Sep 11, 2026 | JP Morgan INITIATE | Overweight |
| Sep 4, 2026 | Citigroup INITIATE | Buy |
| Aug 6, 2026 | Truist Securities MAINTAIN | Buy |
| Aug 6, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Savitz Ryan EVP, CFO & CBO Nov 12, 2026 | EXERCISE | $29.2K |
Savitz Ryan EVP, CFO & CBO Nov 12, 2026 | SELL | $1.6M |
Savitz Ryan EVP, CFO & CBO Nov 12, 2026 | EXERCISE | $361.6K |
Savitz Ryan EVP, CFO & CBO Nov 11, 2026 | EXERCISE | $38.0K |
Savitz Ryan EVP, CFO & CBO Nov 11, 2026 | SELL | $274.1K |
Savitz Ryan EVP, CFO & CBO Nov 11, 2026 | EXERCISE | $28.7K |
Savitz Ryan EVP, CFO & CBO Nov 10, 2026 | SELL | $230.8K |
Savitz Ryan EVP, CFO & CBO Nov 10, 2026 | EXERCISE | $28.3K |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | -$1.03 | -$1.12–-$0.93 | +5.2% | $460.3K |
| Current FY | -$3.60 | -$3.77–-$3.46 | +5.6% | $2.5M |
| Next FY | -$4.35 | -$5.36–-$3.47 | +5.7% | $2.0M |
Short side
FINRA· Oct 30, 2026SecBot reports
18 filings · 5 press releases · 3 bullish · 3 bearish · 1 mixed · 11 neutral- NEUTRAL SC 13G/ANov 16, 2026
T. Rowe Price Investment Management, Inc. filed an amended Schedule 13G disclosing a 10.5% passive stake in Dianthus Therapeutics as of September 30, 2026, up from a prior undisclosed level. This is a routine passive stake increase by a large asset manager and does not signal activist intent.
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL 144Nov 9, 2026
Ryan Savitz, an officer of Dianthus Therapeutics, filed a Form 144 notice of intent to sell…
The Form 144 signals intent to sell, but the sale may not be executed. Monitor subsequent Form 4 filings to confirm actual sales. The officer's option exercise and sale plan could indicate a desire…
- NEUTRAL 8-KNov 4, 2026
Dianthus Therapeutics reported Q3 2026 financial results with a net loss of $46.6M ($0.81 per…
Key near-term catalysts are the Phase 2 MoMeNtum MMN top-line results in December 2026 and CAPTIVATE Part A CIDP results by YE 2027. The 75% interim response rate in CAPTIVATE supports the program's…
- NEUTRAL PRESS-RELEASENov 4, 2026
Dianthus Therapeutics reported Q3 2026 net loss of $46.6M ($0.81 per share), wider than the $36.8M…
Watch for Phase 2 MoMeNtum top-line results in December 2026, which will be a key catalyst for the MMN program. The CIDP CAPTIVATE Part A results by YE'27 and gMG EMERGE results in 2H'28 are…
All DNTH filing & press-release reports (23)
- SC 13G/A reportNov 16, 2026
- 144 reportNov 9, 2026
- 8-K reportNov 4, 2026
- PRESS-RELEASE reportNov 4, 2026
- INST-CLUSTER reportOct 30, 2026
- SC 13G reportOct 30, 2026
- INST-CLUSTER reportOct 12, 2026
- CLUSTER reportAug 11, 2026
- CLUSTER reportAug 11, 2026
- CLUSTER reportAug 11, 2026
- CLUSTER reportAug 11, 2026
- 144 reportAug 10, 2026
- PRESS-RELEASE reportJun 29, 2026
- 8-K reportJun 12, 2026
- INST-CLUSTER reportJun 11, 2026
- 8-K reportMay 5, 2026
- CLUSTER reportMar 12, 2026
- CLUSTER reportMar 12, 2026
- PRESS-RELEASE reportMar 12, 2026
- 8-K reportMar 12, 2026
- PRESS-RELEASE reportMar 10, 2026
- PRESS-RELEASE reportMar 9, 2026
- PRESS-RELEASE reportMar 8, 2026